Does prescribing medications that carry a boxed warning from the U.S. Food and Drug Administration (FDA), also known as a black box warning, automatically meet criteria for the high risk of morbidity from additional diagnostic testing or treatment as part of the E/M risk category for MDM? ...
Subscribe or sign in to view the full article.
Article Overview
This article addresses a common coding question about whether medications with FDA boxed warnings automatically qualify for the high-risk element of E/M medical decision-making. It discusses the relationship between FDA safety warnings and CPT E/M risk criteria, including the general type of monitoring referenced in the 2022 CPT code set and the broader distinction between high-risk and moderate-risk drug management.
Why This Topic Matters
Coders, auditors, and clinicians need to understand how FDA drug warnings fit into E/M risk assessment so that documentation is evaluated against the correct coding framework rather than assumed rules from drug labeling. The article helps prevent overinterpretation of boxed warnings when determining medical decision-making level.
What You Will Learn
- How FDA boxed warnings are distinguished from E/M medical decision-making risk criteria
- What general types of monitoring are referenced in the CPT 2022 E/M guidance
- How medication management may be considered within different E/M risk categories
- Why boxed warning status alone is not the same as a high-risk designation
Who Should Read This
- Medical coders
- Coding auditors
- Compliance staff
- Physicians and other clinicians
- Revenue cycle professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com